These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 10359669

  • 41. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
    Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL.
    FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
    [Abstract] [Full Text] [Related]

  • 42. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
    Sode K, Usuzaka E, Kobayashi N, Ochiai S.
    Biochem Biophys Res Commun; 2005 Sep 23; 335(2):432-6. PubMed ID: 16081040
    [Abstract] [Full Text] [Related]

  • 43. The N Terminus of α-Synuclein Forms Cu(II)-Bridged Oligomers.
    Drew SC.
    Chemistry; 2015 May 04; 21(19):7111-8. PubMed ID: 25757154
    [Abstract] [Full Text] [Related]

  • 44. Neurodegenerative disease: amyloid pores from pathogenic mutations.
    Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT.
    Nature; 2002 Jul 18; 418(6895):291. PubMed ID: 12124613
    [Abstract] [Full Text] [Related]

  • 45. Emerging Approaches to Investigate the Influence of Transition Metals in the Proteinopathies.
    Lermyte F, Everett J, Brooks J, Bellingeri F, Billimoria K, Sadler PJ, O'Connor PB, Telling ND, Collingwood JF.
    Cells; 2019 Oct 10; 8(10):. PubMed ID: 31658742
    [Abstract] [Full Text] [Related]

  • 46. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):54-8. PubMed ID: 19576880
    [Abstract] [Full Text] [Related]

  • 47. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
    Di Scala C, Yahi N, Flores A, Boutemeur S, Kourdougli N, Chahinian H, Fantini J.
    Biochim Biophys Acta; 2016 Feb 01; 1862(2):213-22. PubMed ID: 26655601
    [Abstract] [Full Text] [Related]

  • 48. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation.
    Fernández CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM.
    EMBO J; 2004 May 19; 23(10):2039-46. PubMed ID: 15103328
    [Abstract] [Full Text] [Related]

  • 49. Alpha-synuclein aggregation.
    Bodles AM, Irvine GB.
    Protein Pept Lett; 2004 Jun 19; 11(3):271-9. PubMed ID: 15182228
    [Abstract] [Full Text] [Related]

  • 50. [Alpha-synucleinopathies].
    Ferrer I.
    Neurologia; 2001 Apr 19; 16(4):163-70. PubMed ID: 11412709
    [Abstract] [Full Text] [Related]

  • 51. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY, Lansbury PT.
    Biochemistry; 2003 Apr 08; 42(13):3696-700. PubMed ID: 12667059
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization.
    Nielsen MS, Vorum H, Lindersson E, Jensen PH.
    J Biol Chem; 2001 Jun 22; 276(25):22680-4. PubMed ID: 11312271
    [Abstract] [Full Text] [Related]

  • 54. Dopamine and Cu+/2+ can induce oligomerization of α-synuclein in the absence of oxygen: Two types of oligomerization mechanisms for α-synuclein and related cell toxicity studies.
    Ha Y, Yang A, Lee S, Kim K, Liew H, Lee SH, Lee JE, Lee HI, Suh YH, Park HS, Churchill DG.
    J Neurosci Res; 2014 Mar 22; 92(3):359-68. PubMed ID: 24288134
    [Abstract] [Full Text] [Related]

  • 55. NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases.
    Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Uéda K, Checler F, Kuroda S.
    Acta Neuropathol; 2002 Dec 22; 104(6):637-48. PubMed ID: 12410385
    [Abstract] [Full Text] [Related]

  • 56. Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways.
    Almandoz-Gil L, Welander H, Ihse E, Khoonsari PE, Musunuri S, Lendel C, Sigvardson J, Karlsson M, Ingelsson M, Kultima K, Bergström J.
    Free Radic Biol Med; 2017 Sep 22; 110():421-431. PubMed ID: 28690195
    [Abstract] [Full Text] [Related]

  • 57. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ.
    Glycobiology; 2005 Dec 22; 15(12):1320-31. PubMed ID: 16037493
    [Abstract] [Full Text] [Related]

  • 58. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations.
    Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ.
    J Biol Chem; 2001 Nov 23; 276(47):43495-8. PubMed ID: 11590163
    [Abstract] [Full Text] [Related]

  • 59. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
    Rekas A, Adda CG, Andrew Aquilina J, Barnham KJ, Sunde M, Galatis D, Williamson NA, Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA.
    J Mol Biol; 2004 Jul 23; 340(5):1167-83. PubMed ID: 15236975
    [Abstract] [Full Text] [Related]

  • 60. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
    El-Agnaf OM, Irvine GB.
    J Struct Biol; 2000 Jun 23; 130(2-3):300-9. PubMed ID: 10940234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.